Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.49 |
| ▸ | PPARD | Q03181 | 11/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 11/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174259 | 0.85 | EPHX2 (0.51) | PPARAPPARDEPHX2PDE2A | |
| SCHEMBL18181376 | 0.77 | PDE2A (0.43) | EPHX2PDE2A | |
| SCHEMBL18174185 | 0.76 | EPHX2 (0.50) | PPARAPPARDEPHX2PPARGPDE2A | |
| SCHEMBL18174275 | 0.76 | EPHX2 (0.50) | PPARAPPARDEPHX2PPARGPDE2A | |
| SCHEMBL20128512 | 0.76 | EPHX2 (0.50) | EPHX2PDE2A | |
| SCHEMBL6611829 | 0.75 | PDE2A (0.47) | EPHX2PDE2A | |
| SCHEMBL20061666 | 0.75 | PDE2A (0.42) | EPHX2PDE2A | |
| SCHEMBL16798243 | 0.74 | LDHA (0.47) | PPARAPPARDPPARG | |
| SCHEMBL16798244 | 0.74 | LDHA (0.50) | PPARAPPARDPPARG | |
| SCHEMBL20132775 | 0.74 | GRB2 (0.54) | EPHX2PPARGPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | PPARA 1521/4885PPARD 1499/4885EPHX2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.